EU approves Giotrif for NSCLC patients with EGFR mutations
The European Commission has granted marketing authorisation for Giotrif (afatinib), from Boehringer, for the treatment of patients with metastatic Non-Small Cell Lung Cancer whose tumours express specific types of epidermal growth factor receptor (EGFR) gene mutations.
Approval was given on the basis of data from the Phase III LUX-Lung 3 trial which showed that patients on afatinib as a first-line treatment lived for 11.1 months without their tumour growing again versus 6.9 months for those treated with pemetrexed/cisplatin. A further analysis showed that NSCLC patients with tumours containing the EGFR mutations Del19 or L858R experienced median progression-free survival of 13.6 months with the drug, versus a PFS of 6.9 months with the comparator.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma